Astra sinks Advent's USD 7.6bn buyout of biotech Sobi
Astrazeneca was the reason that the acquisition of Swedish pharmaceutical firm Sobi failed, as the pharmaceutical giant itself wanted certain assets from the Swedish company, sources say.
By Dinesh Nair and Thomas Mulier, bloomberg
Astrazeneca Plc effectively blocked a USD 7.6bn takeover of Swedish Orphan Biovitrum AB by withholding its 8 percent stake in the drugmaker from a buyout offer by Advent International and Singapore wealth fund GIC, according to people familiar with the situation.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Billion-dollar acquisition of Sobi fails
For subscribers
